These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37352360)

  • 1. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus.
    Wang Z; Li Z; Shi W; Zhu D; Hu S; Dinh PC; Cheng K
    Sci Adv; 2023 Jun; 9(25):eabo4100. PubMed ID: 37352360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    Dulin H; Barre RS; Xu D; Neal A; Vizcarra E; Chavez J; Ulu A; Yang M-S; Khan SR; Wuang K; Bhakta N; Chea C; Wilson EH; Martinez-Sobrido L; Hai R
    J Virol; 2024 Feb; 98(2):e0157123. PubMed ID: 38206036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core.
    Shi R; Zeng J; Xu L; Wang F; Duan X; Wang Y; Wu Z; Yu D; Huang Q; Yao YG; Yan J
    EBioMedicine; 2022 Nov; 85():104297. PubMed ID: 36206623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Huang Y; Shi H; Forgacs D; Ross TM
    Vaccine; 2024 Feb; 42(5):1184-1192. PubMed ID: 38296701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA
    Wu CY; Tseng YC; Kao SE; Wu LY; Hou JT; Yang YC; Hsiao PW; Chen JR
    Antiviral Res; 2023 Dec; 220():105759. PubMed ID: 37984568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.
    Handabile C; Ohno M; Sekiya T; Nomura N; Kawakita T; Kawahara M; Endo M; Nishimura T; Okumura M; Toba S; Sasaki M; Orba Y; Chua BY; Rowntree LC; Nguyen THO; Shingai M; Sato A; Sawa H; Ogasawara K; Kedzierska K; Kida H
    Sci Rep; 2024 Feb; 14(1):4204. PubMed ID: 38378856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.
    Loes AN; Gentles LE; Greaney AJ; Crawford KHD; Bloom JD
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32899480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza.
    Stepanova E; Isakova-Sivak I; Mezhenskaya D; Niskanen S; Matyushenko V; Bazhenova E; Rak A; Wong PF; Prokopenko P; Kotomina T; Krutikova E; Legotskiy S; Neterebskii B; Ostroukhova T; Sivak K; Orshanskaya Y; Yakovlev K; Rudenko L
    Virol J; 2024 Apr; 21(1):82. PubMed ID: 38589848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD.
    Li Y; Liu P; Hao T; Liu S; Wang X; Xie Y; Xu K; Lei W; Zhang C; Han P; Li Y; Jin X; Huan Y; Lu Y; Zhang R; Li X; Zhao X; Xu K; Liao P; Lu X; Bi Y; Song H; Wu G; Zhu B; Gao GF
    Emerg Microbes Infect; 2023 Dec; 12(2):2231573. PubMed ID: 37394992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge.
    Xia M; López K; Vago FS; Huang P; Auguste DI; Jiang W; Auguste AJ; Tan M
    Biotechnol J; 2023 Oct; 18(10):e2300130. PubMed ID: 37300425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Hill-Batorski L; Bowen R; Bielefeldt-Ohmann H; Moser MJ; Matejka SM; Marshall D; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2024 Apr; 42(11):2770-2780. PubMed ID: 38508930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subunit-based influenza/SARS-CoV-2 Omicron combined vaccine induced potent protective immunity in BALB/c mice.
    Zhang N; Ye Z; Li C; Zhou J; Xue W; Xiang L; Chen Y; Chen S; Ye R; Dong J; Zhou J; Jiang S; Han H
    J Med Virol; 2024 Mar; 96(3):e29479. PubMed ID: 38425270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
    Geng Q; Tai W; Baxter VK; Shi J; Wan Y; Zhang X; Montgomery SA; Taft-Benz SA; Anderson EJ; Knight AC; Dinnon KH; Leist SR; Baric RS; Shang J; Hong SW; Drelich A; Tseng CK; Jenkins M; Heise M; Du L; Li F
    PLoS Pathog; 2021 Sep; 17(9):e1009897. PubMed ID: 34492082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
    Horvath D; Temperton N; Mayora-Neto M; Da Costa K; Cantoni D; Horlacher R; Günther A; Brosig A; Morath J; Jakobs B; Groettrup M; Hoschuetzky H; Rohayem J; Ter Meulen J
    Sci Rep; 2023 Mar; 13(1):4648. PubMed ID: 36944687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice.
    Cao K; Wang X; Peng H; Ding L; Wang X; Hu Y; Dong L; Yang T; Hong X; Xing M; Li D; Zhu C; He X; Zhao C; Zhao P; Zhou D; Zhang X; Xu J
    J Virol; 2022 Feb; 96(4):e0157821. PubMed ID: 34908443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.